Structure-Based Design of Recombinant Spike Subunit Vaccine for Coronavirus Diseases
Abstract
Keywords
Full Text:
PDFReferences
P. Zhou et al., “A pneumonia outbreak associated with a new coronavirus of probable bat origin,†Nature, vol. 579, no. 7798, pp. 270–273, Mar. 2020, doi: 10.1038/s41586-020-2012-7.
F. Krammer, “SARS-CoV-2 vaccines in development,†Nature, vol. 586, no. 7830, pp. 516–527, Oct. 2020, doi: 10.1038/s41586-020-2798-3.
N. C. Kyriakidis, A. López-Cortés, E. V. González, A. B. Grimaldos, and E. O. Prado, “SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates,†npj Vaccines, vol. 6, no. 1, p. 28, Dec. 2021, doi: 10.1038/s41541-021-00292-w.
S. C. Pandey, V. Pande, D. Sati, S. Upreti, and M. Samant, “Vaccination strategies to combat novel corona virus SARS-CoV-2,†Life Sci., vol. 256, p. 117956, Sep. 2020, doi: 10.1016/j.lfs.2020.117956.
N. Wang, J. Shang, S. Jiang, and L. Du, “Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses,†Front. Microbiol., vol. 11, Feb. 2020, doi: 10.3389/fmicb.2020.00298.
Y.-D. Li, W.-Y. Chi, J.-H. Su, L. Ferrall, C.-F. Hung, and T.-C. Wu, “Coronavirus vaccine development: from SARS and MERS to COVID-19,†J. Biomed. Sci., vol. 27, no. 1, p. 104, Dec. 2020, doi: 10.1186/s12929-020-00695-2.
X. Han, P. Xu, and Q. Ye, “Analysis of COVIDâ€19 vaccines: Types, thoughts, and application,†J. Clin. Lab. Anal., vol. 35, no. 9, Sep. 2021, doi: 10.1002/jcla.23937.
WHO, “COVID-19 vaccine tracker and landscape,†2021.
B. S. Graham, M. S. A. Gilman, and J. S. McLellan, “Structure-Based Vaccine Antigen Design,†Annu. Rev. Med., vol. 70, no. 1, pp. 91–104, Jan. 2019, doi: 10.1146/annurev-med-121217-094234.
P. V’kovski, A. Kratzel, S. Steiner, H. Stalder, and V. Thiel, “Coronavirus biology and replication: implications for SARS-CoV-2,†Nat. Rev. Microbiol., vol. 19, no. 3, pp. 155–170, Mar. 2021, doi: 10.1038/s41579-020-00468-6.
S. Susilawati, R. Falefi, and A. Purwoko, “Impact of COVID-19’s Pandemic on the Economy of Indonesia,†Budapest Int. Res. Critics Inst. Humanit. Soc. Sci., vol. 3, no. 2, pp. 1147–1156, 2020, doi: 10.33258/birci.v3i2.954.
IMF, “Global Recovery Continues, but The Momentum Has Weakened and Uncertainty has Increased,†2021.
D. X. Liu, J. Q. Liang, and T. S. Fung, “Human Coronavirus-229E, -OC43, -NL63, and -HKU1 (Coronaviridae),†in Encyclopedia of Virology, Elsevier, 2021, pp. 428–440.
I. M. Artika, A. K. Dewantari, and A. Wiyatno, “Molecular biology of coronaviruses: current knowledge,†Heliyon, vol. 6, no. 8, p. e04743, Aug. 2020, doi: 10.1016/j.heliyon.2020.e04743.
D. Schoeman and B. C. Fielding, “Coronavirus envelope protein: current knowledge,†Virol. J., vol. 16, no. 1, p. 69, Dec. 2019, doi: 10.1186/s12985-019-1182-0.
M. A. Tortorici et al., “Structural basis for human coronavirus attachment to sialic acid receptors,†Nat. Struct. Mol. Biol., vol. 26, no. 6, pp. 481–489, Jun. 2019, doi: 10.1038/s41594-019-0233-y.
X. Ou et al., “Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV,†Nat. Commun., vol. 11, no. 1, p. 1620, Dec. 2020, doi: 10.1038/s41467-020-15562-9.
J. Shang et al., “Structural basis of receptor recognition by SARS-CoV-2,†Nature, vol. 581, no. 7807, pp. 221–224, May 2020, doi: 10.1038/s41586-020-2179-y.
S. Jiang, C. Hillyer, and L. Du, “Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses,†Trends Immunol., vol. 41, no. 5, pp. 355–359, May 2020, doi: 10.1016/j.it.2020.03.007.
Y. W. Kam et al., “Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcγRII-dependent entry into B cells in vitro,†vaccine, vol. 25, no. 4, pp. 729–740, Jan. 2007, doi: 10.1016/j.vaccine.2006.08.011.
L. Dai and G. F. Gao, “Viral targets for vaccines against COVID-19,†Nat. Rev. Immunol., vol. 21, no. 2, pp. 73–82, Feb. 2021, doi: 10.1038/s41577-020-00480-0.
W. S. Lee, A. K. Wheatley, S. J. Kent, and B. J. DeKosky, “Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies,†Nat. Microbiol., vol. 5, no. 10, pp. 1185–1191, Oct. 2020, doi: 10.1038/s41564-020-00789-5.
L. Min and Q. Sun, “Antibodies and Vaccines Target RBD of SARS-CoV-2,†Front. Mol. Biosci., vol. 8, Apr. 2021, doi: 10.3389/fmolb.2021.671633.
F. Amanat et al., “A serological assay to detect SARS-CoV-2 seroconversion in humans,†Nat. Med., vol. 26, no. 7, pp. 1033–1036, Jul. 2020, doi: 10.1038/s41591-020-0913-5.
D. Adney et al., “Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas,†Viruses, vol. 11, no. 3, p. 212, Mar. 2019, doi: 10.3390/v11030212.
J. Li, L. Ulitzky, E. Silberstein, D. R. Taylor, and R. Viscidi, “Immunogenicity and Protection Efficacy of Monomeric and Trimeric Recombinant SARS Coronavirus Spike Protein Subunit Vaccine Candidates,†Viral Immunol., vol. 26, no. 2, pp. 126–132, Apr. 2013, doi: 10.1089/vim.2012.0076.
L. Jiaming et al., “The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection,†vaccine, vol. 35, no. 1, pp. 10–18, Jan. 2017, doi: 10.1016/j.vaccine.2016.11.064.
Y. Zhou, S. Jiang, and L. Du, “Prospects for a MERS-CoV spike vaccine,†Expert Rev. Vaccines, vol. 17, no. 8, pp. 677–686, Aug. 2018, doi: 10.1080/14760584.2018.1506702.
G. W. Carnell et al., “SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses,†J. Virol., vol. 95, no. 15, Jul. 2021, doi: 10.1128/JVI.00203-21.
P. Pino et al., “Trimeric SARS-CoV-2 Spike Proteins Produced from CHO Cells in Bioreactors Are High-Quality Antigens,†Processes, vol. 8, no. 12, p. 1539, Nov. 2020, doi: 10.3390/pr8121539.
D. Watterson et al., “Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2,†Clin. Transl. Immunol., vol. 10, no. 4, Jan. 2021, doi: 10.1002/cti2.1269.
J. G. Liang et al., “S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates,†Nat. Commun., vol. 12, no. 1, Dec. 2021, doi: 10.1038/s41467-021-21634-1.
J. Ma et al., “Cryo-electron Microscopy Structure of S-Trimer, a Subunit Vaccine Candidate for COVID-19,†J. Virol., vol. 95, no. 11, May 2021, doi: 10.1128/jvi.00194-21.
Y. Tao, S. V Strelkov, V. V Mesyanzhinov, and M. G. Rossmann, “Structure of bacteriophage T4 fibritin: A segmented coiled coil and the role of the C-terminal domain,†Structure, vol. 5, no. 6, pp. 789–798, 1997, doi: 10.1016/S0969-2126(97)00233-5.
T. Li et al., “SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates,†Emerg. Microbes Infect., vol. 9, no. 1, pp. 2076–2090, 2020, doi: 10.1080/22221751.2020.1821583.
Y. He, J. Li, S. Heck, S. Lustigman, and S. Jiang, “Antigenic and Immunogenic Characterization of Recombinant Baculovirus-Expressed Severe Acute Respiratory Syndrome Coronavirus Spike Protein: Implication for Vaccine Design,†J. Virol., vol. 80, no. 12, pp. 5757–5767, Jun. 2006, doi: 10.1128/JVI.00083-06.
M. V. Sinegubova, N. A. Orlova, S. V. Kovnir, L. K. Dayanova, and I. I. Vorobiev, “High-level expression of the monomeric SARS-CoV-2 S protein RBD 320-537 in stably transfected CHO cells by the EEF1A1-based plasmid vector,†PLoS One, vol. 16, no. 2, p. e0242890, Feb. 2021, doi: 10.1371/journal.pone.0242890.
H. Liu et al., “Improvement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances its Antitumor Activity in vivo,†Sci. Rep., vol. 7, no. 1, p. 8953, Dec. 2017, doi: 10.1038/s41598-017-09518-1.
E. K. Thomas, M. Nakamura, D. Wienke, C. M. Isacke, A. Pozzi, and P. Liang, “Endo180 Binds to the C-terminal Region of Type I Collagen,†J. Biol. Chem., vol. 280, no. 24, pp. 22596–22605, Jun. 2005, doi: 10.1074/jbc.M501155200.
J. Pallesen et al., “Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen,†Proc. Natl. Acad. Sci. U. S. A., vol. 114, no. 35, pp. E7348–E7357, Aug. 2017, doi: 10.1073/pnas.1707304114.
D. Wrapp et al., “Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation,†Science (80-. )., vol. 367, no. 6483, pp. 1260–1263, Mar. 2020, doi: 10.1126/science.abb2507.
C.-L. L. Hsieh et al., “Structure-based design of prefusion-stabilized SARS-CoV-2 spikes,†Science (80-. )., vol. 369, no. 6510, pp. 1501–1505, Sep. 2020, doi: 10.1126/science.abd0826.
R. J. Edwards et al., “Cold sensitivity of the SARS-CoV-2 spike ectodomain,†Nat. Struct. Mol. Biol., vol. 28, no. 2, pp. 128–131, Feb. 2021, doi: 10.1038/s41594-020-00547-5.
C. Seephetdee et al., “Mice immunized with the vaccine candidate hexapro spike produce neutralizing antibodies against sars-cov-2,†Vaccines, vol. 9, no. 5, p. 498, May 2021, doi: 10.3390/vaccines9050498.
W. H. Chen et al., “Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement,†vaccine, vol. 38, no. 47, pp. 7533–7541, Nov. 2020, doi: 10.1016/j.vaccine.2020.09.061.
L. Du et al., “Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity,†Virology, vol. 393, no. 1, pp. 144–150, Oct. 2009, doi: 10.1016/j.virol.2009.07.018.
L. Du et al., “A 219-mer CHO-Expressing Receptor-Binding Domain of SARS-CoV S Protein Induces Potent Immune Responses and Protective Immunity,†Viral Immunol., vol. 23, no. 2, pp. 211–219, Apr. 2010, doi: 10.1089/vim.2009.0090.
A. Wieland and R. Ahmed, “Fc Receptors in Antimicrobial Protection,†2019, pp. 119–150.
J. C. Martyn et al., “Surface display of IgG Fc on baculovirus vectors enhances binding to antigen-presenting cells and cell lines expressing Fc receptors,†Arch. Virol., vol. 154, no. 7, pp. 1129–1138, Jul. 2009, doi: 10.1007/s00705-009-0423-8.
S. Loureiro, E. Robinson, H. Chen, P. Phapugrangkul, C. Colaco, and I. M. Jones, “Virus Glycoproteins Tagged with the Human Fc Domain as Second Generation Vaccine Candidates,†in Innovation in Vaccinology, Dordrecht: Springer Netherlands, 2012, pp. 45–63.
S. K. Wong, W. Li, M. J. Moore, H. Choe, and M. Farzan, “A 193-Amino Acid Fragment of the SARS Coronavirus S Protein Efficiently Binds Angiotensin-converting Enzyme 2,†J. Biol. Chem., vol. 279, no. 5, pp. 3197–3201, Jan. 2004, doi: 10.1074/jbc.C300520200.
W. Ren et al., “Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates,†vaccine, vol. 38, no. 35, pp. 5653–5658, Jul. 2020, doi: 10.1016/j.vaccine.2020.06.066.
L. Du et al., “A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines,†PLoS One, vol. 8, no. 12, p. e81587, Dec. 2013, doi: 10.1371/journal.pone.0081587.
L. Du et al., “Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model,†vaccine, vol. 25, no. 15, pp. 2832–2838, Apr. 2007, doi: 10.1016/j.vaccine.2006.10.031.
S. H. Hong et al., “Immunization with RBD-P2 and N protects against SARS-CoV-2 in nonhuman primates,†Sci. Adv., vol. 7, no. 22, p. eabg7156, May 2021, doi: 10.1126/sciadv.abg7156.
S. Bangaru et al., “Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,†Science (80-. )., vol. 370, no. 6520, pp. 1089–1094, Sep. 2020, doi: 10.1126/science.abe1502.
X. Wen et al., “Inclusion of a universal tetanus toxoid CD4+ T cell epitope P2 significantly enhanced the immunogenicity of recombinant rotavirus ΔVP8* subunit parenteral vaccines,†Vaccine, vol. 32, no. 35, pp. 4420–4427, Jul. 2014, doi: 10.1016/j.vaccine.2014.06.060.
Z. Liu et al., “RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response,†Signal Transduct. Target. Ther., vol. 5, no. 1, p. 282, Dec. 2020, doi: 10.1038/s41392-020-00402-5.
R. N. Kirchdoerfer et al., “Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis,†Sci. Rep., vol. 8, no. 1, p. 15701, Dec. 2018, doi: 10.1038/s41598-018-34171-7.
W. H. Chen et al., “Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate,†J. Pharm. Sci., vol. 106, no. 8, pp. 1961–1970, Aug. 2017, doi: 10.1016/j.xphs.2017.04.037.
W. H. Chen et al., “Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate,†Hum. Vaccines Immunother., vol. 10, no. 3, pp. 648–658, Mar. 2014, doi: 10.4161/hv.27464.
L. Du et al., “Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines,†Nat. Commun., vol. 7, no. 1, p. 13473, Dec. 2016, doi: 10.1038/ncomms13473.
Q. He et al., “COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations.,†Front. Immunol., vol. 12, p. 669339, 2021, doi: 10.3389/fimmu.2021.669339.
C. Keech et al., “Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine,†N. Engl. J. Med., vol. 383, no. 24, pp. 2320–2332, Dec. 2020, doi: 10.1056/NEJMoa2026920.
P. T. Heath et al., “Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine,†N. Engl. J. Med., p. NEJMoa2107659, Jun. 2021, doi: 10.1056/nejmoa2107659.
DOI: http://dx.doi.org/10.18517/ijaseit.13.1.16202
Refbacks
- There are currently no refbacks.
Published by INSIGHT - Indonesian Society for Knowledge and Human Development